^
    Back
    Association details:
    Biomarker:ATM mutation
    Cancer:Urothelial Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Prostate Cancer)
    New
    Title:

    Lynparza (olaparib) Receives Health Canada Approval for the Treatment of BRCA or ATM Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

    Excerpt:
    Health Canada approved Lynparza (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Olaparib in Treating Patients With Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects

    Excerpt:
    Patients must have Clinical Laboratory Improvement Act (CLIA) confirmed presence of a somatic or germline alteration considered pathogenic/likely pathogenic by FM and/or the Genetics Review Panel in one or more of the following genes: BRCA1, BRCA2, ATM, BAP1, FANCF, PALB2, and BRIP1...
    Trial ID:
    NCI-2017-02296
    Test:
    FoundationOne® CDx